Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Portfolio Pulse from
Lucid Diagnostics has signed its first concierge medicine contract with LEAA Health, allowing LEAA's patients access to Lucid's EsoGuard esophageal precancer testing on a cash-pay basis.
February 20, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics has entered into a partnership with LEAA Health to provide EsoGuard esophageal precancer testing to LEAA's concierge patients, potentially increasing Lucid's market reach and revenue.
The partnership with LEAA Health allows Lucid Diagnostics to offer its EsoGuard test to a new patient base, potentially increasing its market reach and revenue. This is a positive development for the company, likely to impact its stock price favorably in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
PAVmed Inc., the parent company of Lucid Diagnostics, may benefit from Lucid's new partnership with LEAA Health, as it could lead to increased revenue and market presence for its subsidiary.
As the parent company of Lucid Diagnostics, PAVmed Inc. stands to benefit from Lucid's partnership with LEAA Health, which could lead to increased revenue and market presence for Lucid, positively impacting PAVmed's financials.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70